The US Food and Drug Administration (FDA) is on the brink of approving a breakthrough drug that could upend the way severe depression is treated.
Johnson & Johnson’s (J&J) esketamine, a close chemical cousin of the anesthetic ketamine, on Tuesday cleared a major hurdle when a panel of outside experts recommended that the FDA approve the treatment.
The fast-acting antidepressant, administered via a nasal spray, is being tested in major depressive disorder and suicidal thinking.
If approved, it would be the first major therapeutic advance for depression since the introduction of Prozac in 1987.
Prozac and other currently available antidepressants take weeks to work and do not help all patients, so esketamine could mark a significant shift in depression therapy.
The panel voted 14-2 with one abstention that the benefits of the drug and a safety program proposed by the company to keep it from being misused outweigh the risks of abuse.
“I believe esketamine has the potential to be a gamechanger in the treatment of depression,” Walter Dunn, a panel member and a psychiatrist at the West Los Angeles Veterans Administration Medical Center, said after the vote. “The rates of response in this treatment-resistant population is better than we’ve seen. The rapid time line of response is better. There’s nothing approved that gets patients better this fast.”
Amid the opioid addiction and overdose epidemic in the US, the panel of experts weighed the abuse potential of ketamine, which at much higher doses is a party drug and can put users into a “k hole,” in which they are unable to interact with the world around them.
In a report ahead of the meeting, agency staff called ketamine abuse “relatively uncommon,” with just 1.3 percent of people over age 12 abusing the drug, lower than the abuse rates for other hallucinogens like ecstasy and LSD.
“Ketamine is a nasty drug,” said Steve Meisel, a panel member and system director of medication safety at Fairview Health Services in Minneapolis. “It’s been around for 50 years. Those of us who have seen it used know the adverse-event profile is large.”
However, Meisel said he was convinced by a patient survey Johnson & Johnson conducted.
“We don’t take the patient voice into account enough,” he said.
Some patients taking esketamine experienced disassociation, an out-of-body experience that the company said cropped up within an hour of treatment and would be monitored in an office setting if it occurs.
Some patients also experienced modest spikes in blood pressure during that window.
Esketamine was developed by the company after a group of researchers discovered that ketamine, an off-patent drug, had a surprisingly rapid antidepressant effect.
Some of the first research showing this dates back to the 1990s, and that work was furthered by the National Institutes of Health before being developed into a pharmaceutical treatment by J&J.
Studies have also shown ketamine has the potential to rapidly reduce suicidal thinking and J&J is studying esketamine in depressed patients on the verge of killing themselves as well.
That data are expected later this year.
The nasal spray is a key part of J&J’s pharmaceutical pipeline, as the company faces flagging sales weighed down by drug-pricing scrutiny and biosimilar competition for one of its biggest drugs, the blockbuster arthritis drug Remicade.
RSS